Abstract 11210: Combined Therapy of Skeletal Myoblast Cell-Sheet Transplantation with Administration of Prostacycline Agonist Makes Left Ventricular Reverse Remodeling on the Impaired Myocardium in Rapid-Pacing Induced End-stage Heart Failure in Canine Heart
Background; Although skeletal myoblast cell-sheet transplantation (SMBCT) has been reported for its therapeutic potential to treat heart failure, angiogenesis induced by SMBCT is not always enough for implanted-myoblast to survive. Slow-releasing form of prostacycline agonist (ONO1301MS®) has recently been known for angiogenesis derived from its cardio-protective effect. We hypothesized that ONO1301MS® may show synergic effect of SMBCT on the impaired myocardium.
Materials and methods; For the heart-failure model, 23 beagles underwent ventricular pacing at 240 beats /min for 8 weeks. 4 weeks after the commence of rapid-pacing, we divided them into 4 groups that received (1) polylactic and glycolic acid polymer (PLGA) injection (Control, n=6), (2) PLGA mixed with prostacycline agonist (ONO1301MS®, n=6), (3) SMBCT (Cell, n=5), and (4) SMBCT and intramyocardial-injection of ONO1301MS® (Hybrid, n=6). Speckle-tracking echocardiography (STE) was performed for the analysis of regional left ventricular (LV) myocardial strains (lateral wall=treatment-side, septal wall=remote-side) and LV dyssynchrony between these 2 areas.
Results; All treatment-groups showed the significant LV reverse remodeling and the recovery of radial, circumferential, and transverse strains at treatment-side compared with the Control group while radial and transverse strains at remote-side were significantly recovered in the Cell and the Hybrid groups. Dyssynchrony at remote-side which was seen in the Control and the ONO1301MS® groups was disappeared in the Cell and the Hybrid groups. Diastolic function indicated by tau (τ) and end diastolic pressure was significantly recovered in the Hybrid group compared with the Control and the Cell groups. (Table.1)
Conclusion; ONO1301MS® enhanced LV reverse remodeling induced by SMBCT in canine DCM model. Hybrid therapy with SMBCT and intramyocardial injection of ONO1301MS® might show adjuvant effect on the end-stage heart failure.
- © 2011 by American Heart Association, Inc.